Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › uveitis

Uveitis

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for uveitis

29 trials tracked for uveitis: 14 in phase 3 or 4 and 10 with published results. The most-cited published study has 664 citations.

29Trials tracked
14Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 4 Phase 3 10 Phase 2 9 Phase 1 3 Other / NA 3
  1. Phase 3 Efficacy and Safety of Adalimumab in Patients With Active Uveitis Completed · 664 cited
  2. Phase 3 Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis Completed · 514 cited
  3. Phase 3 PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial Completed · 212 cited
  4. Phase 3 A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis Completed · 58 cited
  5. Phase 4 Adalimumab in JIA-associated Uveitis Stopping Trial Completed · 24 cited
  6. Phase 3 Adalimumab vs. Conventional Immunosuppression for Uveitis Trial Completed · 23 cited
Show 23 more trials
  1. Phase 3 Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial Completed · 22 cited
  2. Phase 3 Methotrexate and Mycophenolate Mofetil for UVEITIS Completed · 18 cited
  3. Phase 3 Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis Completed · 18 cited
  4. Phase 3 Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis Completed · 10 cited
  5. Phase 4 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed
  6. Phase 4 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed
  7. Phase 4 Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment Completed
  8. Phase 3 First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial Completed
  9. Phase 2 Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Completed
  10. Phase 2 Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis Completed
  11. Phase 2 Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis Completed
  12. Phase 2 Lucentis for Inflammatory Macular Edema Trial Completed
  13. Phase 2 Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis Completed
  14. Phase 2 Topical Interferon Gamma for Macular Edema Secondary to Uveitis Completed
  15. Phase 2 Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study) Completed
  16. Phase 2 Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis Completed
  17. Phase 2 Abatacept in the Treatment of Uveitis Completed
  18. Phase 1 Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis Completed
  19. Phase 1 Sirolimus as Therapeutic Approach to Uveitis Completed
  20. Phase 1 Efalizumab to Treat Uveitis Completed
  21. N/A Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications Completed
  22. N/A Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema Completed
  23. N/A MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301 Completed

Showing the 29 most-cited and recently-updated of 29 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Uveitis: what the trials found

Adalimumab has demonstrated significant efficacy in managing uveitis. Clinical trials showed a statistically significant reduction in time to treatment failure [1, 6] and significant improvements in vitreous haze (VH) grades 5. Additionally, Adalimumab was associated with higher rates of corticosteroid-sparing treatment success within the first 6 months 9, and some studies reported high percentages of patients achieving quiescence over time 8.

Intraocular implants and local injections show varied results for uveitis management. A fluocinolone acetonide intraocular implant significantly reduced uveitis activity compared to other treatments 4, while a dexamethasone intravitreal implant showed significant reduction in central subfield thickness at 12 weeks 10. Periocular triamcinolone (40 mg) demonstrated significant reductions in macular thickness at 8 weeks 7.

Suprachoriodal injections of CLS-TA were associated with a significantly higher number of patients achieving at least a 15-letter improvement in best corrected visual acuity 11 and high rates of patients achieving grade 0 for anterior chamber cells, flare, and vitreous haze 13.

Other systemic treatments include mycophenolate mofetil, which showed success in several phases of treatment 12, and methotrexate, though its superiority over other options was not statistically significant in the studied cohort 14.

Recent results — preliminary, needs further review

  • Ustekinumab reported a median of 118 days until first recurrence (not yet corroborated).
  • Triamcinolone acetonide (Triesence) showed a reduction in vitreous haze grade (not yet corroborated).
  • 4 mg CLS-TA was associated with significant reductions in central subfield thickness in patients with macular edema following uveitis (not yet corroborated).
  • Sarilumab showed a statistically significant decrease in vitreous haze scale at week 16, though it did not show a significant difference in the percentage of participants achieving specific reduction goals compared to the control 19.

For the clinician treating this condition

  • Adalimumab is an established option for reducing treatment failure and improving vitreous haze while facilitating corticosteroid-sparing success.
  • Intraocular implants (fluocinolone acetonide, dexamethasone) and periocular triamcinolone are established interventions for managing uveitis activity and macular thickness.
  • Suprachoriodal CLS-TA injections are associated with significant improvements in visual acuity and clinical markers like anterior chamber cell grade.

AI synthesis of 11 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Hydrogels overcome physiological barriers to improve drug delivery and tissue repair in anterior segment diseases
Ophthalmology Sys. Review
Hydrogels overcome physiological barriers to improve drug delivery and tissue repair in anterior segment diseases Hydrogels Improve Drug Delivery for Various Eye Conditions
This systematic review evaluates hydrogel platforms including adhesive drops, thermosensitive gels, and drug-eluting lenses compared to conv…
New hydrogel technologies may overcome the limitations of standard eye drops to provide longer-lasting treatment for conditions like glaucom…
Frontiers Jul 8, 2026
Systematic review and meta-analysis of uveitis subtypes in European tertiary centers
Ophthalmology Meta-analysis
Systematic review and meta-analysis of uveitis subtypes in European tertiary centers European data show most adult uveitis cases are anterior or non-infectious
This systematic review and meta-analysis of 30 471 patients from European tertiary centers found that anterior uveitis is the most common su…
A large review of 30,471 patients found that over half of uveitis cases were anterior and nearly half were non-infectious across Europe.
May 1, 2026
Systematic review and meta-analysis supports adalimumab plus methotrexate for JIA-associated uveitis
Pediatrics Meta-analysis
Systematic review and meta-analysis supports adalimumab plus methotrexate for JIA-associated uveitis Combination therapy reduces relapse risk in children with eye inflammation from arthritis
This systematic review and meta-analysis of RCTs evaluated adalimumab plus methotrexate in children with juvenile idiopathic arthritis-assoc…
Combining adalimumab with methotrexate lowers relapse risk and helps reduce steroid use in children with arthritis-related eye inflammation.
May 1, 2026
Systematic review links gut dysbiosis to uveitis pathogenesis
Ophthalmology Sys. Review
Systematic review links gut dysbiosis to uveitis pathogenesis Gut health may influence eye inflammation in uveitis
This systematic review summarizes evidence on gut microbiota modulation for uveitis and inflammatory ocular diseases.
A review links gut bacteria imbalance to uveitis, suggesting eye inflammation may be tied to what's happening in your digestive system.
Frontiers Apr 23, 2026
Baricitinib showed limited efficacy in pediatric JIA-uveitis patients refractory to methotrexate or biologics at week 24
Drug Pipeline RCT
Baricitinib showed limited efficacy in pediatric JIA-uveitis patients refractory to methotrexate or biologics at week 24 New Hope for Kids with Stubborn Eye Inflammation
This open-label, active-controlled phase-3 multicenter trial enrolled 30 pediatric patients with juvenile idiopathic arthritis-associated uv…
A new drug shows early promise for children with stubborn eye inflammation who didn't respond to standard treatments, offering hope when oth…
Apr 18, 2026

Questions about uveitis

Is there a link between gut bacteria and the development of uveitis?

Research suggests a link between gut bacteria and uveitis through a concept called the "gut-eye axis," where an imbalance in gut microbes may trigger immune responses that affect the eyes.

Full answer →
Can hydrogels improve drug delivery for treating anterior segment uveitis?

Yes, hydrogels improve drug delivery for anterior uveitis by enhancing bioavailability, extending retention, and enabling synergistic anti-inflammatory effects, as shown in recent studies.

Full answer →
Is anterior uveitis the most common type of uveitis found in Europe?

Yes, anterior uveitis is the most common type of uveitis in Europe, accounting for about 40–52% of cases in studies from tertiary centers.

Full answer →